Oncoprint highlights baseline alterations related to kras g12c and egfr resistance in colorectal cancer patients, suggesting implications for treatment strategies.
Oncoprint of baseline alterations in CRC patients who developed resistance to KRAS G12C and EGFR inhibitors
No takes yet. Share an insight, caveat, or question.
Yaeger et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: